Company Filing History:
Years Active: 2017-2025
Title: Helena Ågerstam: Innovator in Cancer Treatment
Introduction
Helena Ågerstam is a prominent inventor based in Lund, Sweden. She has made significant contributions to the field of cancer treatment, holding a total of seven patents. Her work focuses on innovative methods for treating IL1RAP associated cancers, showcasing her dedication to advancing medical science.
Latest Patents
Among her latest patents, Helena has developed methods for treating IL1RAP associated cancers using anti-human interleukin-1 receptor accessory protein (IL1RAP) antibodies. This invention provides an antibody or an antigen-binding fragment that specifically binds to human IL1RAP, inhibiting the binding of the antibody 'CAN04' to this protein. The applications of these antibodies extend to the treatment and diagnosis of IL-1 associated diseases, including acute myeloid leukemia and melanoma.
Career Highlights
Helena Ågerstam is currently associated with Cantargia AB, a company dedicated to developing innovative cancer therapies. Her work has positioned her as a key figure in the research and development of targeted cancer treatments.
Collaborations
Helena collaborates with notable colleagues such as Thoas Fioretos and Marcus Järås, contributing to a dynamic research environment focused on improving cancer therapies.
Conclusion
Helena Ågerstam's innovative work in cancer treatment through her patents highlights her significant impact on medical research. Her contributions continue to pave the way for advancements in the treatment of IL1RAP associated cancers.